Clinical trial of valproic acid and all‐trans retinoic acid in patients with poor‐risk acute myeloid leukemia

@article{Bug2005ClinicalTO,
  title={Clinical trial of valproic acid and all‐trans retinoic acid in patients with poor‐risk acute myeloid leukemia},
  author={Gesine Bug and Markus Ritter and Barbara Wassmann and Claudia Schoch and Thorsten Heinzel and Kerstin Schwarz and Annette Romanski and Oliver H Kramer and Manuela Kampfmann and Dieter Hoelzer and Andreas Neubauer and Martin Ruthardt and Oliver Gerhard Ottmann},
  journal={Cancer},
  year={2005},
  volume={104}
}
Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, induced in vitro differentiation of primary acute myeloid leukemia (AML) blasts, an effect enhanced by all‐trans retinoic acid (ATRA). Clinical responses to VPA were recently observed in patients with myelodysplastic syndrome (MDS). Herein, the authors have described results of a clinical trial with VPA plus ATRA in 26 patients with poor‐risk AML. 
Translocation positive acute myeloid leukemia associated with valproic acid therapy
TLDR
A case of valproic acid‐related leukemia‐like syndrome with a t(8;16) chromosomal translocation is reported, with the hematological findings completely resolved.
Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes.
TLDR
In the present study, VPA in combination with two differentiating agents, 13-cis retinoic acid and 1,25-dihydroxyvitamin D3, was given to 19 previously untreated patients with MDS or CMML and three patients responded to treatment.
Valproic acid for the treatment of myeloid malignancies
TLDR
In this report, the authors reviewed the in vitro and in vivo data obtained with VPA, and they considered possible combination regimens aimed at improving therapeutic efficacy.
An ATRActive future for differentiation therapy in AML.
TLDR
Preliminary studies suggest that targeting the pathways that modify retinoic acid receptor activity may reactivate the dormant retinic acid-signaling pathway and revive the ability of ATRA to induce myeloid differentiation and apoptosis in non-APL AML.
The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia
TLDR
Treatment with continuous valproic acid and intermittent ATRA plus low-dose cytarabine plus intermittent oral ATRA has a low frequency of side effects and complete hematological remission is seen for a small minority of patients, however, disease stabilization isseen for a subset of AML patients unfit for conventional intensive chemotherapy.
Clinical Trials of Epigenetic Modifiers in the Treatment of Myelodysplastic Syndrome
TLDR
The development of all-trans-retinoic acid for the treatment of acute promyelocytic leukemia has been the outstanding success of this effort.
Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia
TLDR
Evidence is presented that increased thrombopoiesis can occur early during treatment with valproic acid /ATRA /theophyllamine, and the platelet levels may continue to increase and persist at high levels for several weeks following short-term treatment.
The Activity of Valproic Acid in the Treatment of Refractory Hyperleukocytosis in a Child with Acute Lymphoblastic Leukemia
TLDR
The valproic acid used for the treatment of the hyperleukocytosis did not respond to known therapies in a child; lymphoblastic lymphoma developed bone marrow relapse under the treatment is discussed.
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.
TLDR
The addition of ATRA to decitabine resulted in a higher remission rate and a clinically meaningful survival extension in these patients with difficult-to-treat disease, without added toxicity.
Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia—Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation
TLDR
The general experience with valproic acid/ATRA in AML therapy is reviewed and its possible use in low-intensity/toxicity treatment of post-allotransplant AML relapse is discussed.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.
TLDR
VPA is of therapeutic benefit for patients with MDS, and ATRA may be effective when added later, as it is shown to inhibit histone deacetylase activity and to synergize with all-trans retinoic acid in the differentiation induction of acute myelogenous leukemia (AML) blasts in vitro.
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
TLDR
Valproic acid induces differentiation of carcinoma cells, transformed hematopoietic progenitor cells and leukemic blasts from acute myeloid leukemia patients, and tumor growth and metastasis formation are significantly reduced in animal experiments, suggesting that it might serve as an effective drug for cancer therapy.
Effect of polar organic compounds on leukemic cells: Butyrate‐induced partial remission of acute myelogenous leukemia in a child
TLDR
Organic agents that induce cell differentiation may provide additional reagents for the clinical management of selected cases of leukemia and butyrate was the most potent.
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.
TLDR
It was concluded that this higher-dose therapy had no benefit in the postremission management of older patients with de novo AML, and the need to develop novel therapeutic strategies for these patients is suggested.
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.
TLDR
It is concluded that depsipeptide effectively inhibits HDAC in vivo in patients with CLL and AML, but its use in the current schedule of administration is limited by progressive constitutional symptoms.
Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.
TLDR
It is shown that AML1/ETO, the commonest AML-associated fusion protein, is an HDAC-dependent repressor of RA signaling, which relates alteration of the RA pathway to myeloid leukemogenesis and underscores the potential of transcriptional/differentiation therapy in AML.
Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.
TLDR
Clinical treatment with an inhibitor of histone deacetylase induces histone hyperacetylation in target cells and may restore sensitivity to the anti-leukemic effects of all-trans-retinoic acid in acute promyelocytic leukemia.
Report of an international working group to standardize response criteria for myelodysplastic syndromes.
TLDR
An international working group of experienced clinicians involved in the management of patients with MDS reviewed currently used response definitions and developed a uniform set of guidelines for future clinical trials in MDS, aimed at improving communication among investigators and to ensure comparability among clinical trials.
Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways.
TLDR
Findings suggest that VPA exerts an anti-leukemic effect by both caspase-dependent and -independent apoptotic signaling pathways.
International scoring system for evaluating prognosis in myelodysplastic syndromes.
TLDR
Compared with prior risk-based classifications, this International Prognostic Scoring System provides an improved method for evaluating prognosis in MDS and should prove useful for more precise design and analysis of therapeutic trials in this disease.
...
1
2
3
...